Logo

Castle Biosciences

Castle Biosciences Q4 Revenues Jump 53 Percent as Firm Beats Analyst Expectations

Castle also reported full-year revenues at the top end of previously issued guidance and offered full-year 2023 guidance ahead of Wall Street expectations.

Castle Biosciences Estimates 2022 Revenues in Line With Prior Projections

The company said it expects full-year revenues of at least $132 million to $137 million, with test volumes up significantly across the majority of its menu.

In Brief This Week: Biocept, Thermo Fisher, Biodesix, More

News items for the week of Nov. 21, 2022.

Castle Bio Q2 Growth Driven by Skin Cancer Testing as New Acquisitions Boost Sales
Premium

The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories. 

Local Coverage Determinations Roundup: Castle Bio, SkylineDx

Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx. 

May 11, 2022

Castle Bio Adds New Outcome Data for Melanoma Assay, Shares Early Info on Skin Disease Test
Premium

May 9, 2022

Castle Biosciences Q1 Revenues Grow 18 Percent

May 2, 2022

Omics Tools and MDx Stocks Down Across the Board in April, Following Broader Market

Apr 29, 2022

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

Apr 29, 2022

In Brief This Week: Natera, Caris Life Sciences, Fulgent Genetics, Castle Biosciences, More

Apr 5, 2022

Castle Biosciences to Acquire AltheaDx for $65M

Apr 1, 2022

In Brief This Week: Biocept, SeqLL, Castle Biosciences, VolitionRx, More

Mar 2, 2022

Castle Bio Adds Data for DecisionDx Melanoma Assay, Eyes Squamous Cell Carcinoma Reimbursement
Premium

Feb 28, 2022

Castle Biosciences Q4 Revenues Grow 45 Percent

Feb 3, 2022

Castle Biosciences Working With NCI on SEER Registry Study of DecisionDx-Melanoma

Feb 1, 2022

Stocks of Genomics Tools and MDx Firms Hit Hard in January Sell-off

Jan 10, 2022

CareDx, Castle Bio, Lucira Health, Others Announce Preliminary Q4, FY21 Earnings Results

Dec 1, 2021

GenomeWeb Index Falls 6 Percent in November as Emergence of Omicron Spooks Markets

Nov 8, 2021

Castle Biosciences Q3 Revenues Rise 54 Percent

Oct 27, 2021

Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio
Premium

Oct 19, 2021

Castle Biosciences Acquires Cernostics for up to $80M

Sep 16, 2021

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

Aug 24, 2021

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

Aug 9, 2021

Castle Biosciences Q2 Revenues Rise 79 Percent

Jul 16, 2021

People in the News: New Appointments at Castle Biosciences, Oxford Nanopore, PGDx, More

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.